Previous 10 | Next 10 |
home / stock / sphry / sphry news
Summary AstraZeneca plans to grow beyond 2025 by building its innovation pipeline. Investors in the target benefit when a big pharma company acquires an emerging company. Starpharma is an example of a company that might be of interest to a big pharma acquirer. Rarely, emer...
NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-demand viewing. REGISTER NOW OR...
Starpharma presents compelling data in Prostate Cancer at ESMO PR Newswire MELBOURNE, Australia , Sept. 12, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Devel...
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...
Merck ( NYSE: MRK ) signed an agreement with Australian biotech Starpharma ( OTCQX:SPHRY ) to develop antibody drug conjugates (ADCs). Starpharma said the new DEP program will generate and evaluate additional DEP ADCs. The two companies had previousl...
Starpharma signs new DEP® agreement with MSD PR Newswire MELBOURNE, Australia , Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP ® Research Agreement with MSD, the trade n...
The treatment window for COVID is very narrow; this limits the value of even effective treatments. Molnupiravir effectiveness ~30%; Paxlovid seems more effective in trials, but the real world awaits. Molnupiravir is not transforming for Merck, but Paxlovid at worst means a major b...
Melbourne biotech Starpharma (OTCQX:SPHRY) announces positive interim results from the prostate cancer cohort in its ongoing Phase 2 trial of DEP cabazitaxel. Starpharma's interim results in prostate cancer show that one or more efficacy signals were observed in 100% of patients ass...
Starpharma releases positive DEP® phase 2 interim results in prostate cancer PR Newswire MELBOURNE, Australia , Nov. 26, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer coho...
Molnupiravir results are striking for very early treatment, but this doesn't compare with vaccination; the time window for effect is short and the trial was mostly with unvaccinated people. Merck has a Phase 3 trial testing if molnupiravir can prevent infection of a person exposed to ...
News, Short Squeeze, Breakout and More Instantly...
Starpharma Hldgs S/Adr Company Name:
SPHRY Stock Symbol:
OTCMKTS Market:
Uni Charm Corporation ADR (UNICY) is expected to report for Q2 2023 Clarus Therapeutics Hldgs (CRXTQ) is expected to report for quarter end 2023-06-30 Bed Bath & Beyond Inc. (BBBYQ) is expected to report for Q2 2024 CalAmp Corp. (CAMP) is expected to report $-0.04 for Q2 2024 ...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...
Verbund AG ADR (OEZVY) is expected to report for Q2 2023 Adtran Networks SE (ADVOF) is expected to report for Q2 2023 OMV AG (OMVJF) is expected to report $1.66 for Q2 2023 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 Minim Inc (MINM) is expected to r...